Biogen Leans On Plegridy To Help Extend The Life Of Avonex
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug maker reports positive late-stage data for its newest multiple sclerosis product. The pegylated interferon could help its existing injectable interferon franchise maintain share against new oral options.